Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

Changzhou Hansoh Pharmaceutical Co., Ltd.

Zhang, Ling

Ling Zhang

Weikang Tao

Feng He

Fanglong Yang

Hua Ying

Lei Zhang

Lianshan Zhang

Zhen Zhang

Liangliang Zheng

Qiyue Hu

Xiaomin Zhang

Yayuan Fu

Yang Wang

Dongbing Cui

Yifang Wang

Jiajian Liu

Jinping Shi

Ting Zhang

Qing Dong

Jianyan Xu

Chunfei Wang

Jihui Han

Jiakang Sun

Haoying Zhang

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Fused imidazole derivative, preparation method therefor, and medical use thereof

Disclosed by the present invention are an anti-B7H3 antibody-exatecan analog conjugate, a preparation method therefor and an anti-tumor medicinal use thereof.

Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Anti-Aβ antibodies and antigen-binding fragments thereof

Growing community of inventors

Shanghai, China

Ling Zhang